A well-prepared self-affirmed GRAS dossier may already contain much of the scientific information needed to support an FDA GRAS notice. However, converting an existing dossier for FDA review should not be treated as a simple reformatting exercise.
The first step is a comprehensive gap assessment comparing the existing GRAS dossier, the ingredient as it is manufactured and used today, the current scientific evidence, and FDA’s requirements for a GRAS notice.
That assessment should determine whether the ingredient identity and manufacturing information remain current, specifications are adequately supported, intended uses and dietary exposure calculations remain accurate, and the safety narrative reflects the totality of available evidence. Particular attention should be paid to whether sufficient evidence supporting the GRAS conclusion is publicly available to establish general recognition among qualified experts.
FDA GRAS notices are organized into seven parts, covering everything from administrative statements and ingredient characterization to dietary exposure, safety evidence, and supporting references. Preparing an existing self-affirmed GRAS dossier for FDA review means ensuring that each of these areas is complete, current, scientifically defensible, and structured for submission.
Join our free webinar, GRAS Under Pressure: Preparing for New FDA Regulations, on September 9 at 1:00 PM ET.
For companies with an existing self-affirmed GRAS conclusion, preparing a GRAS dossier for FDA review may appear relatively straightforward. After all, a scientifically robust self-affirmed determination and a GRAS conclusion submitted to FDA through the notification program are based on the same underlying GRAS safety standard.
The important difference is that an FDA GRAS notice places the supporting conclusion and scientific evidence directly before the Agency for evaluation.
Under FDA’s current voluntary notification framework, the Agency evaluates the information presented in a GRAS notice, together with other information available to FDA, to determine whether the notice provides a sufficient basis for the notifier’s GRAS conclusion. FDA may respond with a “no questions” letter, determine that the notice does not provide a sufficient basis for the conclusion, or cease its evaluation at the notifier’s request.
A “no questions” letter is not FDA approval or affirmation that the substance is GRAS. It indicates only that, based on the information submitted and other information available to FDA, the Agency has no questions at that time regarding the notifier’s GRAS conclusion. The notifier remains responsible for that conclusion.
This distinction has become particularly relevant following FDA’s August 2026 proposal to generally require GRAS notification for uses of human and animal food substances introduced into interstate commerce under the GRAS provision, subject to specified exceptions. The proposal would also create an optional, time-limited streamlined submission process for certain intended uses of substances introduced into interstate commerce before the effective date of a final rule. That streamlined process would not require submission of the underlying safety evidence, and inclusion on FDA’s public list would not constitute an FDA determination that the use is GRAS. FDA could subsequently require a full GRAS notice or food additive petition. Importantly, none of these proposed requirements are currently in effect.
For companies considering a full GRAS notice—whether voluntarily today or because one may later be required—the objective should be the same: determine whether the existing GRAS dossier is ready to withstand FDA review and identify what needs to be updated before submission. Companies with eligible uses already in interstate commerce should also evaluate whether the proposed streamlined submission process may be available and whether relying on that process, rather than immediately submitting a full GRAS notice, is strategically appropriate.
GRAS—Generally Recognized as Safe—is a regulatory pathway through which the intended use of a substance can be excluded from the definition of a food additive requiring premarket approval.
The key point is that GRAS status applies to a substance under its intended conditions of use. An existing GRAS conclusion therefore cannot be assessed solely by asking whether the ingredient itself has previously been determined to be safe. Its identity, manufacturing process, specifications, food applications, use levels, dietary exposure, and supporting safety evidence all need to correspond to the conditions being evaluated.
FDA’s GRAS notice framework organizes this information into seven parts:
For companies starting with an existing self-affirmed GRAS dossier, these seven parts provide a practical framework for determining whether the existing documentation is ready for FDA review.
Before rewriting or restructuring an existing GRAS dossier, the first step should be a gap assessment against FDA requirements.
A dossier may have been scientifically appropriate when the original GRAS conclusion was reached but no longer accurately reflect the ingredient or available evidence today. Manufacturing processes can change. Specifications can evolve. New applications can increase exposure. New toxicological studies can be published. An older literature search may no longer represent the totality of available evidence.
The gap assessment should therefore examine both regulatory completeness and scientific currency.
| GRAS Dossier Part | What to Evaluate During the Gap Assessment |
| Part 1: Signed Statements and Certification | Confirm the notifier, ingredient, intended conditions of use, basis for the GRAS conclusion, required statements and certifications, and the completeness and accuracy of administrative information. |
| Part 2: Identity, Manufacturing & Specifications | Confirm that ingredient identity, composition, manufacturing process, raw materials, specifications, analytical methods, batch data, stability information, and technical effect accurately represent the ingredient currently marketed. |
| Part 3: Dietary Exposure | Review intended food categories and use levels, current U.S. consumption data, estimated dietary intake, background exposure from other dietary sources, and assumptions used in the exposure assessment. |
| Part 4: Self-Limiting Levels of Use | Determine whether technological, organoleptic, or other practical factors naturally limit the amount of the substance that can be used in food and whether those limits are appropriately documented. |
| Part 5: Common Use Before 1958 | If the GRAS conclusion relies on common use in food, verify that sufficient evidence demonstrates substantial consumption by a significant number of consumers before January 1, 1958. |
| Part 6: Narrative | Assess the totality of the safety evidence, literature search, toxicology, ADME where relevant, human data, general recognition, contradictory evidence, and whether unpublished information is being used appropriately. |
| Part 7: Supporting Data & Information | Verify that every source cited in the safety narrative is identified, accessible where required, correctly classified as published or unpublished, and consistent with the conclusions presented in the dossier. |
The outcome should be a clear roadmap separating information that can be carried forward, information that needs to be updated, and substantive data gaps that may require additional scientific work.
Part 1: Signed Statements and Certification
Part 1 establishes the administrative and regulatory foundation of the GRAS notice.
When adapting a self-affirmed GRAS dossier, companies should verify that the substance, notifier, intended conditions of use, and basis for the GRAS conclusion are described consistently throughout the submission.
This is also an opportunity to ensure that the intended uses in the original determination still correspond with actual or proposed commercialization. If food categories, use levels, or other conditions have expanded since the original conclusion, those changes may affect other sections of the GRAS dossier, particularly dietary exposure and the overall safety assessment.
Part 1 should not simply be copied from an older determination. The statements and certifications should reflect the submission being made to FDA and the current conditions of intended use.
Part 2: Identity, Method of Manufacture, Specifications, and Physical or Technical Effect
Part 2 establishes exactly what substance is being evaluated.
For an older GRAS dossier, this can be one of the most important areas to reassess. Changes to raw materials, processing aids, fermentation organisms, extraction processes, purification steps, manufacturing locations, or specifications may affect whether the ingredient currently being produced remains adequately represented by the original safety assessment.
The review should consider ingredient identity and composition, physical and chemical characteristics, manufacturing controls, specifications, analytical methods, impurities and contaminants, batch analyses, and stability information where applicable.
Specifications should also be evaluated against the material used in relevant safety studies. If the commercial ingredient has changed materially from the test article supporting the original safety conclusion, additional justification or scientific assessment may be necessary.
The goal is to demonstrate a clear connection between the ingredient being marketed, the ingredient described in the GRAS dossier, and the ingredient supported by the safety evidence.
Part 3: Dietary Exposure
Safety cannot be evaluated independently of exposure.
Part 3 describes expected dietary exposure to the notified substance from the proposed conditions of use, while also considering exposure from other dietary sources where applicable.
When converting an existing self-affirmed GRAS dossier, the exposure assessment should be reviewed to determine whether the food categories, maximum use levels, consumption assumptions, and underlying U.S. food-consumption data remain appropriate.
This becomes particularly important when an ingredient has expanded into additional product categories since the original GRAS conclusion.
A gap assessment may identify a need to update the estimated daily intake or cumulative exposure analysis before FDA notification. The resulting exposure estimate should also align with the exposure levels evaluated in the toxicological and other safety evidence discussed in Part 6.
Part 4: Self-Limiting Levels of Use
Some substances have practical limits on how much can be incorporated into food because higher concentrations make the food unpalatable or technologically impractical.
Where applicable, Part 4 explains these self-limiting characteristics.
For an existing GRAS dossier, the assessment should determine whether self-limitation is relevant to the proposed conditions of use and whether any statements regarding practical use limits are adequately supported.
If there is no applicable self-limiting level, the dossier should address the section accordingly rather than leaving an unexplained gap in the submission.
Part 5: Experience Based on Common Use in Food Before 1958
Most modern GRAS conclusions are established through scientific procedures rather than experience based on common use in food.
However, FDA’s framework allows a GRAS conclusion to be based on common use in food before January 1, 1958, where the required historical evidence can be established.
If an existing dossier relies on this pathway, the gap assessment should examine whether there is sufficient evidence demonstrating a substantial history of consumption by a significant number of consumers before 1958.
This is a high evidentiary threshold. Historical use should not be assumed simply because an ingredient or related botanical, microorganism, or food source has a long history of consumption.
Where the GRAS conclusion is instead based on scientific procedures, Part 5 should clearly reflect that distinction.
Part 6: Narrative Supporting the GRAS Conclusion
Part 6 is the scientific core of the GRAS dossier.
The narrative needs to explain why the available data, information, methods, and scientific principles support the conclusion that qualified experts would generally recognize the substance as safe under its intended conditions of use.
For an older self-affirmed dossier, this section deserves particularly careful review.
The literature search should be updated to identify relevant evidence published since the original assessment. New toxicological, clinical, mechanistic, exposure, or other safety information should be evaluated alongside the evidence already relied upon.
Importantly, the assessment should consider the totality of available evidence, not simply studies supporting the desired conclusion. Information that appears inconsistent with or potentially adverse to the GRAS conclusion needs to be identified, evaluated, and appropriately discussed.
Another critical consideration is general recognition. FDA has specifically identified the availability of key safety information as relevant when evaluating whether a notice provides a sufficient basis for a GRAS conclusion. The GRAS conclusion therefore cannot depend solely on confidential or unpublished evidence unavailable to the broader community of qualified experts.
Unpublished information can provide important corroborative support, but the publicly available evidence must be sufficient to establish general recognition of safety.
Current FDA regulations already require notifiers to identify information they consider exempt from disclosure under the Freedom of Information Act and to explain how a GRAS conclusion can be supported when qualified experts do not have access to relevant non-public safety information. Under FDA’s 2026 proposed rule, notifiers would be required to identify claimed exemptions at the time of submission, and failure to do so could be treated as indicating that the information is not exempt or that confidentiality has been waived.
Part 7: List of Supporting Data and Information
Part 7 provides the supporting references for the scientific conclusions presented throughout the GRAS dossier.
Every publication, study, report, analytical document, and other source relied upon should be accurately identified and traceable to the discussion in the dossier.
When preparing an older self-affirmed dossier for FDA review, this section should be reconciled against the updated Part 6 narrative. New literature needs to be added, outdated or superseded information appropriately addressed, and published versus unpublished evidence clearly distinguished.
This final reconciliation can also uncover inconsistencies that might otherwise be missed—for example, a safety study discussed in the narrative but absent from the reference list, or an older reference that no longer supports the current manufacturing process or intended conditions of use.
A clean and complete Part 7 helps demonstrate that the scientific narrative is supported by an organized and transparent evidence base.
The result of the gap assessment should not simply be a checklist of missing documents.
It should provide a regulatory and scientific strategy for bringing the existing GRAS dossier up to FDA-facing standards.
Some gaps may be relatively straightforward, such as updating administrative information, obtaining recent batch analyses, refreshing a literature search, or recalculating dietary exposure. Others can have greater implications, such as a significant manufacturing change, expanded conditions of use, newly identified safety signals, insufficient publicly available evidence, or a toxicological data gap.
Those issues should be resolved before the GRAS dossier is finalized for FDA review.
This is also why companies should avoid assuming that an existing self-affirmed conclusion can simply be submitted to FDA unchanged. The more useful question is whether the evidence and documentation supporting that conclusion remain sufficient under the ingredient’s current conditions of intended use and current FDA expectations.
Join dicentra on September 9 at 1:00 PM ET for GRAS Under Pressure: Preparing for New FDA Regulations, a free webinar examining FDA’s proposed mandatory GRAS notification framework and what it could mean for industry.
Dylan Fronda, Toxicology and Product Safety Manager at dicentra, will discuss the implications for existing GRAS dossiers, FDA review and public disclosure, the proposed streamlined submission pathway, and how companies can participate in the public comment period before the December 9 deadline.
dicentra supports companies in developing, reviewing, and defending GRAS determinations for food, beverage, and nutraceutical ingredients. For companies with an existing self-affirmed GRAS conclusion, our team can assess the current GRAS dossier against FDA requirements and develop a strategy for addressing identified regulatory or scientific gaps.
Our GRAS consulting and scientific capabilities include:
dicentra combines regulatory, toxicology, scientific, and CRO capabilities, allowing identified gaps to be addressed as part of an integrated GRAS strategy rather than treating dossier preparation as a documentation exercise alone.
With more than 20 years of regulatory and scientific experience, we support both established ingredients and novel or complex substances across categories including botanical extracts, probiotics and microbial ingredients, enzymes, fermentation-derived materials, proteins, peptides, amino acids, lipids, fibers, carbohydrates, minerals, electrolytes, vitamins, and other functional ingredients.
The objective is not simply to prepare a submission. It is to develop a scientifically defensible GRAS dossier that supports regulatory review, commercial due diligence, and the ingredient’s long-term use in the U.S. market.
Have an existing self-affirmed GRAS dossier that you are considering submitting to FDA?
dicentra can review your existing documentation, perform a comprehensive gap assessment against FDA GRAS notice requirements, identify scientific or regulatory deficiencies, and support preparation of an FDA-ready GRAS dossier.
Contact dicentra to discuss your GRAS dossier and FDA notification strategy.